Update on options for treatment of metastatic castration-resistant prostate cancer

OncoTargets and Therapy

Volumn 3, Issue , 2010, Pages 39-51

  Vishnu, Prakash ^a   Tan, Winston W ^a  

^a MAYO CLINIC   (United States)

Author keywords

Castration resistant prostate cancer; Circulating tumor cells; Mechanisms of resistance; Novel therapies

Indexed keywords

ABIRATERONE; ANTINEOPLASTIC AGENT; ASCENTAR; BEVACIZUMAB; CALCITRIOL; CAPECITABINE; CARBOPLATIN; CLUSTERIN; DASATINIB; DOCETAXEL; ENDOTHELIN RECEPTOR ANTAGONIST; EPIRUBICIN; EPOTHILONE B; EPOTHILONE DERIVATIVE; ERIBULIN; FLUORODIHYDROTESTOSTERONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IXABEPILONE; MDV 3100; NAVELBINE; OBLIMERSEN; OGX 011; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR; PROVENGE; RADIOPHARMACEUTICAL AGENT; SATRAPLATIN; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; FATIGUE; FEVER; HEMATOLOGIC DISEASE; HUMAN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROSTATE CARCINOMA; RASH; REVIEW; RIGOR; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TUMOR CELL; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS;

EID: 77953442022     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. American Chemical Society. Website. Available from: http://www.acs.org/. Accessed on December 10, 2009.
2. DeVita VT, Lawrence TS, Rosenberg SA. Cancer Principles and Practice of Oncology. 8th ed. 2008;1392-1445.
3. Cancer of the prostate. Tables and figures #23. 2009. Available from: http://seer.cancer.gov/csr/1975_2006/results_merged/sect_23_prostate.pdf. Accessed on December 10, 2009.
4. Lassi K, Dawson NA. Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol. 2009;21:260-265.
5. Attar RM, Takimoto CH, Gottardis MM. castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res. 2009;15(10):3251-3255.
6. Helo P, Cronin AM, Danila DC, et al. Circulating prostate tumor cells detected by RT-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem. 2009;55(4):765-773.
7. Scher HI, Morris MJ, Kelly WK, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-1159.
8. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17(11):3461-3467.
9. Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009;27(15):2450-2456.
10. Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol. 2002;34(11):1430-1448.
11. So A, Hadaschik B, Sowery R, et al. The role of stress proteins in prostate cancer. Curr Genom. 2007;8(4):252-261.
12. Miyake H, Yamanaka K, Muramaki M, et al. Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncol Rep. 2005;14(5):1371-1375.
13. Zellweger T, Miyake H, July LV, et al. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the anti-apoptotic gene clusterin. Neoplasia. 2001;3(4):360-367.
14. Pins MR, Fiadjoe JE, Korley F, et al. Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prostate Cancer Prostatic Dis. 2004;7(3):243-248.
15. Chi KN, Hotte SJ, Yu E, et al. Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone vs docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2009;27(15s): Abstract # 5012.
16. Dehdashti F, Picus J, Michalski JM, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging. 2005;32(3):344-350.
17. Larson SM, Morris M, Gunther I, et al. Tumor localization of 16b-18F-Fluoro-5b-dihydrotestosterone vs 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45(3):366-373.
18. Morris MJ, Schoder H, Smith-Jones P, et al. Pilot trial of [18F]fluoro-dihydro-testosterone (FDHT) and [18F]fluoro-2-deoxy-D-glucose (FDG) PET imaging in patients with castrate metastatic prostate cancer (CMPC). Proc Am Soc Clin Oncol. (2006 Prostate Cancer Symposium); Abstract #144.
19. National Institutes of Health. Clinical Trials. 2009. Available from: http://clinicaltrials.gov/. Accessed on December 10, 2009.
20. Scher HI, Beer TM, Higano CS, et al. Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). J Clin Oncol. 2009;27(15s): Abstract #5011.
21. de Bono JS, Scher HI, Montgomery BR, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302-6309.
22. Groves-Kirkby N. Biomarkers: Circulating tumor cells in prostate cancer. Nature Rev Urol. 2009;6(5):238.
23. Tannock IF, de Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512.
24. Berthold DR, Pond G, de Wit R, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of Tax 327. J Clin Oncol. 2007;25(18s): Abstract #5005.
25. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-1520.
26. Koletsky AJ, Guerra ML, Kronish L. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer. Cancer J. 2003;9(4):286-292.
27. Di Lorenzo G, Pizza C, Autorino R, et al. Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. Eur Urol. 2004;46(6):712-716.
28. Hahn NM, Marsh S, Fisher W, et al. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res. 2006;12(20):6094-6099.
29. Vaishampayan UN, Heilbrun H, Eliason J, et al. Phase II trial of docetaxel and capecitabine combination in metastatic androgen independent prostate cancer (AIPC). Proc Am Soc Clin Oncol. (2007 Prostate Cancer Symposium); Abstract # 239.
30. Dahut WL, Gulley JL, Arlen PM et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22(13):2532-2539.
31. Oh WK, Halabi S, Kelly KW et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003;98(12):2592-2598.
32. Brausi M, Jones WG, Fossa SD, et al. High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group. Eur J Cancer. 1995;31A(10):1622-1626.
33. Petrioli R, Paolelli L, Francini E, et al. Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. Urology. 2007;69(1):142-146.
34. Schwartz GG, Oeler TA, Uskokovic MR, et al. Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs. Anticancer Res. 1994;14(3A):1077-1081.
35. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol. 2007;25(6):669-674.
36. Chao DT, Korsmeyer SJ. BCL-2 FAMILY: Regulators of cell death. Ann Rev Immunol. 1998;16(1):395-419.
37. Tolcher AW, Kuhn J, Schwartz G, et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone refractory prostate cancer. Clin Cancer Res. 2005;11(10):3854-3861.
38. Sternberg CN, Dumez H, Van Poppel H, et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol. 2009;20(7):1264-1269.
39. Miyake H, Hara I, Kamidono S, et al. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncol Rep. 2003; 10(2):469-473.
40. Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst. 2005;97(17)1287-1296.
41. Mani S, Macapinlacc M Jr, Goel S, et al. The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drug. 2004;15(6):553-558.
42. Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005;23(7):1439-1446.
43. Hussain M, Tangen C, Lara P, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol. 2005;23(34):8724-8729.
44. Rosenberg JE, Kelly WK, Michaelson MD, et al. A randomized phase II study of ixabepilone (Ix) or mitoxantrone and prednisone (MP) in patients with taxane (T)-resistant hormone refractory prostate cancer (HRPC). J Clin Oncol. 2005;23(16s): Abstract # 4566.
45. Chi KN, Beardsley EK, Venner PM, et al. A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel. J Clin Oncol. 2008;26(15s): Abstract # 5166.
46. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4(7):1086-1095.
47. de Bono JS, Maroto P, Calvo E, et al. Phase II study of eribulin mesylate (E7389) in patients (patients) with metastatic castration-resistant prostate cancer (CRPC) stratified by prior taxane therapy. Proc Am Soc Clin Oncol. (2009 Genitourinary Cancer Symposium); Abstract # 166.
48. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005;65:9185-9189.
49. Edwards J, Krishna NS, Witton CJ, et al. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res. 2003;9(14):5271-5281.
50. Tatarov O, Mitchell TJ, Seywright M, et al. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res. 2009;15(10):3540-3549.
51. Koreckij T, Nguyen H, Brown LG, et al. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer. 2009;101:263-68.
52. Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2009;15(23):OF1-8.
53. Higano C, Saad F, Somer B, et al. A phase III trial of GVAX immunotherapy for prostate cancer vs docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Proc Am Soc Clin Oncol. (2009 Genitourinary Cancer Symposium); Abstract # LBA150.
54. Small E, Demkov T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel vs docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Proc Am Soc Clin Oncol. (2009 Genitourinary Cancer Symposium); Abstract # 7.
55. Tannock IF, de Wit R, Berry WR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756-1764.
56. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17(8):2506-2513.
57. Berry W, Dakhil S, Modiano M, et al. Phase III study of mitoxantrone plus low dose prednisone vs low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002;168(6):2439-2443.
58. Garmey EG, Sartor O, Halabi S, et al. Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol. 2008;6(2):118-122, 127-132.
59. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res. 2001;7(7):1932-1936.
60. Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: A phase 2 study. Eur Urol. 2008;54(5):1089-1096.
61. Dahut WL, Scripture C, Posadas E, et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res. 2008;4(1):209-214.
62. Latif T, Wood L, Connell C, et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs. 2005;23(1):79-84.
63. Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs prednisone alone in patients with hormone-refractory prostate cancer. Oncology. 2005;68(1):2-9.
64. Sartor AO, Petrylak DP, Witjes JA, et al. Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): Overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial. J Clin Oncol. 2008;26(15s): Abstract #5003.
65. Beardsley EK, Saad F, Eigl B, et al. A phase II study of patupilone in patients (patients) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel. J Clin Oncol. 2009;27(15s): Abstract # 5139.
66. Rosenberg JE, Weinberg V, Kelly KW, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007;110(3):556-563.
67. Thakkar SG, Choueiri TK, Garcia JA. Endothelin receptor antagonists: Rationale, clinical development, and role in prostate cancer therapeutics. Curr Oncol Rep. 2006;8(2):108-113.
68. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med. 1995;1(9):944-949.
69. Carducci MA, Saad F, Abrahamsson P, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110: 1959-1966.
70. Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005;96(9):1241-1246.
71. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787-790.
72. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24(19):3089-3094.